MedTrace Logo

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

NCT05150652 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2026-01-07

No results posted yet for this study

Summary

The goal of this study is to access whether treatment of early state estrogen-rich breast cancers with neoadjuvant endocrine therapy will result in higher rates of margin negativity on lumpectomy specimen.

Conditions

Interventions

DRUG

Anastrozole 1mg

Participants will take 1mg of anastrozole once daily, orally, for up to six cycles of 28 days.

DRUG

Letrozole 2.5mg

Participants will take 2.5mg of Letrozole once daily, orally, for up to six cycles of 28 days.

DRUG

Exemestane 25 mg

Participants will take 25mg of Exemestane once daily, orally, for up to six cycles of 28 days.

DRUG

Tamoxifen

Participants will take 20mg of Tamoxifen once daily, orally, for up to six cycles of 28 days.

Sponsors & Collaborators

  • Irada Ibrahim-zada

    lead OTHER

Principal Investigators

  • Irada Ibrahim-zada, MD · University of Kentucky

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-18
Primary Completion
2025-12-09
Completion
2026-06-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05150652 on ClinicalTrials.gov